Our previous studies have defined reactive stroma in human prostate cancer and have developed the differential reactive stroma (DRS) xenograft model to evaluate mechanisms of how reactive stroma promotes carcinoma tumorigenesis. Analysis of several normal human prostate stromal cell lines in the DRS model showed that some rapidly promoted LNCaP prostate carcinoma cell tumorigenesis and others had no effect. These differential effects were due, in part, to elevated angiogenesis and were transforming growth factor (TGF)-B1 mediated. The present study was conducted to identify and evaluate candidate genes expressed in prostate stromal cells responsible for this differential tumor-promoting activity. Differential cDNA microarray analyses showed that connective tissue growth factor (CTGF) was expressed at low levels in nontumorpromoting prostate stromal cells and was constitutively expressed in tumor-promoting prostate stromal cells. TGF-B1 stimulated CTGF message expression in nontumor-promoting prostate stromal cells. To evaluate the role of stromalexpressed CTGF in tumor progression, either engineered mouse prostate stromal fibroblasts expressing retroviral-introduced CTGF or 3T3 fibroblasts engineered with mifepristoneregulated CTGF were combined with LNCaP human prostate cancer cells in the DRS xenograft tumor model under different extracellular matrix conditions. Expression of CTGF in tumorreactive stroma induced significant increases in microvessel density and xenograft tumor growth under several conditions tested. These data suggest that CTGF is a downstream mediator of TGF-B1 action in cancer-associated reactive stroma and is likely to be one of the key regulators of angiogenesis in the tumor-reactive stromal microenvironment. (Cancer Res 2005; 65(19): 8887-95) 
Introduction
Our previous studies have characterized reactive stroma in human prostate cancer progression and have developed the differential reactive stroma (DRS) xenograft model to address the role of reactive stroma in experimental prostate tumorigenesis. These studies have shown that reactive stroma initiates during prostatic intraepithelial neoplasia, exhibits a myofibroblast wound repair stromal phenotype, is tumor promoting, and is mediated, in part, by transforming growth factor (TGF)-h1 action (1-3). Our studies have also shown that reactive stroma was essential for inducing early angiogenesis and acted to stimulate both the incidence and rate of LNCaP prostate cancer cell tumorigenesis in DRS model xenografts (2) . These studies showed that differential LNCaP tumor progression is based on the type of stroma in the xenograft tumor and the stromal response to TGF-h1.
Connective tissue growth factor (CTGF) has emerged as a potent mediator of TGF-h1 action in wound repair stromal responses and in fibrosis disorders (4) (5) (6) . CTGF is a member of the CCN gene family ( for CTGF, Cyr61, and Nov; refs. [7] [8] [9] . This family includes six structural and functional related proteins: CTGF (10, 11); cysteine-rich 61 (Cyr61; ref. 12); nephroblastoma overexpressed (NovH; ref. 13) ; and Wnt-1-induced signaling protein (WISP) 1, WISP2, and WISP3 (14) . The CCN family members (excluding WISP2) share four conserved structural modules with sequence homologies similar to insulin-like growth factor-binding protein, von Willebrand factor, thrombospondin, and cysteine knot (8) . CTGF message is potently stimulated by TGF-h1 (15) (16) (17) (18) (19) and likely mediates TGF-h1-induced collagen expression in wound repair fibroblasts (20) . CTGF is expressed by several stromal cell types, including endothelial cells, fibroblasts, smooth muscle cells, and myofibroblasts, and some epithelial cell types in diverse tissues. Consistent with its role in connective tissue biology, CTGF enhances stromal extracellular matrix synthesis (16) and stimulates proliferation, cell adhesion, cell spreading, and chemotaxis of fibroblasts (10, 16, 21) . CTGF was also shown to stimulate smooth muscle cell proliferation and migration (22) . In addition, CTGF is a potent stimulator of endothelial cell adhesion, proliferation, migration, and angiogenesis in vivo (23) (24) (25) . As might be predicted, CTGF is expressed in the reactive stromal compartment of several epithelial cancers, including mammary carcinoma, pancreatic cancers, and esophageal cancer (26) (27) (28) . Expression of CTGF is also observed in several stromal cell disorders, including angiofibromas, infantile myofibromatosis, malignant hemangiopericytomas, fibrous histiocytomas, and chondrosarcomas (29, 30) . Accordingly, CTGF is considered to be a profibrosis marker (31) . Together, these findings suggest that CTGF is a key regulatory factor for stromal tissue biology in wound repair and cancer progression; however, this has not yet been tested in vivo using engineered stromal cells.
Expression of TGF-h1 is elevated in most epithelial carcinoma cells (32) and our previous studies have shown that TGF-h1 is a critical regulator of carcinoma-associated reactive stroma, angiogenesis, and reactive stroma promotion of tumor progression in LNCaP xenograft tumors (3) . Because TGF-h1 stimulates CTGF expression in stromal cells (15) , including human prostate stromal cells (19) , CTGF has accordingly emerged as a candidate downstream effector of TGF-h1 action in reactive stroma.
The DRS model system was specifically developed to evaluate differential gene expression in the reactive stromal compartment in xenografts composed of tissue-specific cancer cells and coordinate stromal cells (2, 3) . These studies showed that two different human prostate stromal cell lines, HTS-2T and HTS-40C, exhibited differential effects in reactive stroma-induced angiogenesis and tumorigenesis of LNCaP prostate cancer cells (2) . The present study was conducted to assess candidate genes responsible for the differential functions. We report here that CTGF was differentially expressed in tumor-promoting prostate stromal cell lines and that CTGF expression is stimulated by TGF-h1 in prostate stromal cells. In addition, we show that overexpression of CTGF in engineered prostate stromal cells in the DRS LNCaP xenograft model resulted in significantly elevated angiogenesis and LNCaP tumorigenesis in vivo.
Materials and Methods
Cell lines. LNCaP human prostate carcinoma cells were purchased from American Type Culture Collection (ATCC, Manassas, VA) and maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT), 100 units/mL penicillin, and 100 Ag/mL streptomycin (Sigma, St. Louis, MO). The HTS-2T and HTS-40C normal human prostate stromal cell lines were established in our laboratory (2) and cultured in Bfs medium: DMEM (Invitrogen) supplemented with 5% FBS (Hyclone), 5% Nu serum (BD Biosciences, Bedford, MA), 0.5 Ag/mL testosterone, 5 Ag/mL insulin, 100 units/mL penicillin, and 100 Ag/mL streptomycin (Sigma). The Phoenix E packaging cell line was received from ATCC (by permission from Dr. Gary Nolan, Stanford University, Stanford, CA) and maintained in DMEM with high glucose (Invitrogen) supplemented with 10% heat inactivated FBS (Hyclone), 2 mmol/L glutamine (Invitrogen), and antibiotics as described above.
The mouse prostate stromal cell line, C57B, was derived from an 8-week C57BL/6 male mouse. The ventral prostate was removed, cut into 1 mm 3 cubes, and placed in wells of a six-well culture plate in Bfs medium and cultured at 37jC with 5% CO 2 . Monolayers of stromal cells extended from the explants and, at confluence, the explants were removed and stromal cells were continued in culture by routine serial passage. C57B cells were positive for androgen receptor, vimentin, and smooth muscle a-actin with low expression of calponin (data not shown), similar to human prostate stromal cell lines we have reported previously (2) . C57B cells were used at passages 15 to 25 for all experiments.
The GeneSwitch-3T3 cell line expressing the GeneSwitch regulatory protein from the pSwitch vector was purchased from Invitrogen. GeneSwitch-3T3 cells and derivative engineered cell lines were maintained in DMEM (Invitrogen) supplemented with 10% FBS (Hyclone), 100 units/mL penicillin, 100 Ag/mL streptomycin (Sigma), and Hygromycin B and/or Zeocin (Invitrogen) as described below.
cDNA microarray analysis. HTS-2T and HTS-40C cells were cultured in Bfs medium to 80% confluence. Total RNA was extracted from each cell line with RNA STAT-60 total RNA/mRNA isolation reagent (Tel-test, Inc., Friendswood, TX) following the instructions of the manufacturer. Microarray analysis was done using 30 Ag of total RNA. The cDNA reverse transcription and fluorescent labeling reactions were carried out using Cy3-labeled nucleotides for control (HTS-2T) and Cy5-labeled nucleotides for experimental (HTS-40C) samples as described previously (33) . A microarray chip carrying 6,000 human cDNAs obtained from Baylor Microarray Core Facility was used. The hybridized slide was scanned with an Axon 4000A dual-channel scanner (Axon Instruments, Foster City, CA) and the data was analyzed using Gene Pix v. 3.0 software package (Axon). Genes were considered up-regulated if the expression was changed at least 3-fold from the control. Data with low signal intensity, high background, and high variability were eliminated.
Reverse transcription-PCR. Differential expression of CTGF in HTS-2T and HTS-40C cells was assessed by reverse transcription -PCR (RT-PCR) analysis. HTS-2T and HTS-40C cells were cultured in Bfs medium to 80% confluence and total RNA was extracted with the RNeasy Miniprep kit (Qiagen, Inc., Valencia, CA). CTGF amplification with primer 5V -GGTTAC-CAATGACAACGCCT-3V and primer 5V -TGCTCCTAAAGCCACACCTT-3V were used to monitor CTGF expression, by using the TaqMan one-step RT-PCR kit (Applied Biosystems, Foster City, CA).
To determine the effects of TGF-h1 on CTGF expression, HTS-2T cells were cultured to 80% confluence, exposed to M 0 serum-free media (MCDB 110 supplemented with insulin, transferrin, and sodium selenite; Sigma Diagnostics) for 24 hours, followed by 100 pmol/L (2.5 ng/mL) porcine TGF-h1 (R&D Systems, Minneapolis, MN) or vehicle control in M 0 media treatment for an additional 24 hours before total RNA extraction as described above. 18S rRNA amplifications with 18S rRNA primers (provided in the TaqMan one-step RT-PCR kit) were used for total RNA loading control. RT-PCR reactions were carried out in 50 AL total volume with 80 ng of total RNA and 32 pmol of each primer. First-strand synthesis was done at 48jC for 30 minutes. For CTGF amplification, PCR cycles were run at 95jC for 15 seconds, 60jC for 2 minutes, for a total of 28 cycles. For 18S rRNA amplification, PCR cycles were run at 95jC for 15 seconds, 60jC for 1 minute, for a total of 20 cycles. The PCR products were electrophoresed through a 2% agarose gel, visualized with ethidium bromide, and photographed. A similar RT-PCR procedure was carried out to monitor CTGF expression in HTS-2T and HTS-40C cells, with a total RNA of 200 ng per reaction.
Retroviral infection. The pRc/CMV-CTGF plasmid containing human CTGF cDNA was a kind gift from Dr. Gary Grotendorst (Lovelace Respiratory Research Institute, Albuquerque, NM; ref. 16, 26) . For the construction of pBMN-CTGF-I-enhanced green fluorescent protein (EGFP) vector for retroviral delivery of CTGF, the human CTGF cDNA coding sequence was excised with EcoRI from pRc/CMV-CTGF vector and ligated into the pBMN-I-EGFP retroviral vector kindly provided by Dr. Gary Nolan with the same restriction site. Clones were sequenced to ensure correct CTGF cDNA orientation and sequence.
The pBMN-CTGF-I-EGFP vector (bicistronic) or pBMN-I-EGFP control vector were transfected into Phoenix E cells with a calcium phosphate transfection kit (Invitrogen) following a modified protocol. In brief, Phoenix cells were seeded at 1.5 Â 10 6 cells in a 6 cm culture plate 24 hours before transfection. For transfection, 10 Ag of DNA and 61 AL of 2 mol/L CaCl 2 were brought to 0.5 mL with double-distilled water and added dropwise to 0.5 mL of 2Â HBS, while aerating with a pipette, and followed by 30-minute incubation at room temperature to form fine precipitates. To Phoenix cells in 6 cm plates in 3 mL media, 2 AL of 50 mmol/L chloroquine stock were added. Five minutes later, DNA/CaHPO 4 precipitates were added dropwise, followed by overnight incubation at 37jC. Medium was replaced 24 hours after transfection and plates were incubated at 32jC. Virus in the supernatant from each retrovirusproducing line was collected 48 hours after transfection and filtered (0.45 Am). Three milliliters of viral supernatant with additional 5% FBS, 5% Nu serum (BD Biosciences), 0.5 Ag/mL testosterone (Sigma), 5 Ag/mL insulin, and 5 Ag/mL polybrene was applied immediately to C57B prostate stromal cells at 60% to 80% confluence in T25 flask. Infection was carried out at 37jC. Viral supernatant was replaced with fresh Bfs medium 24 hours after infection. Expression of retroviral construct was confirmed by counting the percentage of green fluorescent (GFP positive) C56B cells per Â100 field. Infected cultures with a >90% green fluorescent cells per field were passaged and frozen (À80jC) in 4 Â 10 6 cells/vial aliquots for use in DRS xenografts.
3T3 cell GeneSwitch system. The GeneSwitch system (Invitrogen) was used to engineer 3T3 fibroblast cells with mifepristone (RU 486) inducible expression of a V5-His tagged CTGF protein. GeneSwitch-3T3 cells expressing the GeneSwitch regulatory protein from the pSwitch vector were purchased from Invitrogen. For the construction of pGene CTGF-V5-His vector, the human CTGF cDNA was PCR amplified from pRc/CMV-CTGF with primers 5V -CTAGGATCCGCCCGCAGTGCC-3V (Bam HI) and primer 5V -TCT-CTGGGGCCCTGCCATGTCTCCGTACATCTTC-3V (ApaI). PCR cycles were run at 95jC for 30 seconds, 60jC for 30 seconds, and 72jC for 80 seconds for a total of 20 cycles after first incubation at 95jC for 2 minutes. The PCR reaction was incubated at 72jC for another 10 minutes for final extension. PCR products were purified with QIAquick PCR purification kit (Qiagen). After digestion with BamHI and limited digestion with ApaI (to avoid internal ApaI site along CTGF cDNA sequence), the 1.1 kb CTGF insert was gel purified and cloned in frame into the pGene/V5-His A vector (Invitrogen). Fidelity was confirmed by sequence analysis. The pGene CTGF-V5-His vector or pGene/V5-His empty vector control was transfected into GeneSwitch-3T3 cell line (Invitrogen) with FuGENE 6 transfection reagent (Roche Diagnostics Corp., Indianapolis, IN), following the protocol of the manufacturer. Stable transfected GeneSwitch-3T3 cells were selected and maintained in media (as described previously) containing 50 Ag/mL of Hygromycin B and 200 Ag/mL of Zeocin. Mifepristone (100 pmol/L) was used to induce CTGF-V5-His fusion protein expression. Regulated expression was confirmed by Western blot analysis of secreted proteins.
To render engineered GeneSwitch-3T3 pGene CTGF-V5-His and GeneSwitch-3T3 pGene/V5-His cells less proliferative and less tumorigenic for use in the DRS xenograft model, the cells were irradiated with increasing doses of g-irradiation. The g-irradiation dosage of 800 rad was chosen for DRS xenograft tumor experiments because it resulted in viable cells with a low proliferation rate and high expression of mifepristone-inducible CTGF-V5-His protein in vitro (Western blot, data not shown).
Western blot analysis. For V5 Western blot, conditioned medium from GeneSwitch-3T3 pGene CTGF-V5-His cells induced with 100 pmol/L mifepristone (or vehicle control) was electrophoresed through a 12% SDS-PAGE gel. Proteins were transferred onto nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA) and incubated in PBS buffer with 5% nonfat milk at 4jC overnight. Mouse anti-V 5 monoclonal antibody (Invitrogen), diluted at 1:5,000, was used as primary antibody to detect the presence of CTGF-V5-His fusion protein, and incubated for 2 hours at room temperature. Secondary antibody was biotin-conjugated sheep anti-mouse IgG (Sigma), diluted at 1:1,000, and incubated for 1 hour at room temperature. A streptavidin-horseradish peroxidase conjugate (Amersham Pharmacia Biotech UK, Ltd., Buckinghamshire, United Kingdom) diluted at 1:1,000 was incubated for 30 minutes at room temperature. Protein bands were detected by incubation with ECL+ Western blotting detection system (Amersham Biosciences) for 5 minutes at room temperature followed by exposure to Hyperfilm ECL from Amersham Pharmacia Biotech.
For CTGF Western blot, C57B CTGF and control cells were grown in Bfs to 80% confluence, then switched to serum-free M 0 media for 2 days. The media were collected and concentrated 20-fold by Amicon Ultra 4 centrifugation (5000 MWCO; Millipore, Billerica, MA). The concentrated samples were electrophoresed through a 12% SDS-PAGE gel and proteins were transferred onto Immobilon-P (Millipore). The membrane was incubated in PBS buffer with 2.5% normal donkey serum at 4jC overnight. The immunoblot protocol was the same as above, except the primary antibody was goat anti-CTGF antibody L-20 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), diluted at 1:400, and secondary antibody was biotinconjugated donkey anti-goat antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA), diluted at 1:40,000.
Animals and preparation of differential reactive stromal xenografts. Athymic NCr-nu/nu male homozygous nude mice, 6 to 8 weeks of age, were purchased from Charles River Laboratories (Wilmington, MA). All experiments were in compliance with the NIH Guide for the Care and Use of Laboratory Animals and according to the institutional guidelines of Baylor College of Medicine.
DRS xenograft tumors were generated following procedures we have published previously (2, 3, 34) . Briefly, frozen aliquots of LNCaP human prostate cancer cells (16 Â 10 6 ) and the engineered stromal cells-C57B-CTGF (8 Â 10 6 cells), C57B-control (8 Â 10 6 cells), and g-irradiated GeneSwitch-3T3 pGene CTGF-V5-His cells (4 Â 10 6 cells)-were thawed in a 37jC water bath for 1 to 2 minutes and washed once with 10 mL RPMI supplied with 10% serum ( for LNCaP cells) or with 10 mL DMEM supplied with 10% serum ( for stromal cells) in 15 mL conical tubes. The cells were pelleted at 1,400 Â g for 2 minutes and resuspended in 6 mL RPMI 1640 with 10% FBS. The LNCaP cells were then combined with stromal cells, mixed well, and pelleted again at 1,400 Â g for 2 minutes. The supernatant was aspirated to either 300 AL ( for Matrigel experiments) or 200 AL [for growth factor-reduced (GFR) matrix mixture experiments] and cells were resuspended in the remaining medium. Cells were incubated on ice for 1.5 minutes and then combined with either 0.5 mL of Matrigel (Becton Dickinson, Bedford, MA) or 0.6 mL of a GFR matrix mixture composed of a 1:1 ratio of neutralized Vitrogen 100 (99.9% collagen type I; Cohesion, Palo Alto, CA) and GFR Matrigel (Becton Dickinson). In all experiments, the final volume was 800 AL. The cell and matrix mixture was drawn into a 1 mL syringe fitted with a 20-gauge needle. After switching to a 25-gauge needle, 100 AL of the cell-matrix suspension was injected s.c. in each lateral flank of adult NCr-nu/nu male mice.
To induce expression of CTGF-V5-His, mice with DRS xenografts composed of LNCaP cells combined with g-irradiated GeneSwitch-3T3 pGENE CTGF-V5-His cells received mifepristone (Sigma) or vehicle control (sesame seed oil; Sigma) at 0.5 mg/kg administered as 100 AL i.p. injections at the time of tumor injection and repeated every 48 hours until tumors were harvested. This mifepristone dose was based on protocols shown previously to induce consistent gene expression in vivo and had no affect on xenograft tumor weight or volume (data not shown). All mifepristone experiments are in accordance with our approved Animal Use Protocols and institutional guidelines of Baylor College of Medicine.
Tumors were collected at different time points between days 10 and 21 postinoculation. For the experimental sets of LNCaP cells combined with C57B-CTGF or C57B-control cells, the tumors were photographed in situ for GFP expression to confirm gene expression using a fluorescent dissecting microscope. The tumors were weighed, measured in three dimensions, and fixed in 4% paraformaldehyde (neutral buffered) at 4jC overnight, washed three times in PBS, and processed for paraffin embedding. Tumors were paraffin-embedded and 5 Am sections were cut and mounted onto ProbeOn Plus slides (Fisher Scientific, Pittsburgh, PA). Sections were either stained with H&E for histologic analysis or processed for immunohistochemistry.
Immunohistochemistry. Primary antibodies were as follows: antimouse CD31/platelet/endothelial cell adhesion molecule 1 antibody (rat monoclonal MEC13.3; BD PharMingen, San Diego, CA); anti-V5 mouse monoclonal antibody 46-0705 (Invitrogen); rabbit anti-GFP antibody A-11122 (Molecular Probes, Eugene, OR); goat anti-CTGF antibody L-20 (Santa Cruz). Secondary antibodies were as follows: biotin-conjugated goat anti-rat IgG (BD PharMingen) for CD31, biotin-conjugated Universal Secondary (Invitrogen) for V5, biotin-conjugated goat anti-rabbit IgG B8895 (Sigma) for GFP, and biotin-conjugated donkey anti-goat antibody (Jackson ImmunoResearch Laboratories). Specificity of each primary antibody has been evaluated previously (refs. 2, 3, 34; and unpublished data).
Immunostaining was done with the MicroProbe Staining System (Fisher Scientific) following our protocol published previously (2, 3, 34) . Reagents formulated for use with capillary action systems were purchased from Open Biosystems (Huntsville, AL) and used according to the protocol of the manufacturer. In brief, tissues were deparaffinized using Auto Dewaxer and cleared with Auto Alcohol. Brigati's iodine and Auto Prep were used to improve tissue antigenicity. Antigen retrieval were used in CD31, V5, and CTGF staining. For CD31 staining, tissues were incubated in 0.1% trypsin (Zymed, South San Francisco, CA) for 10 minutes at 37jC; for V5 and CTGF staining, tissues were subjected to high-temperature-steamer treatment in 10 mmol/L sodium citrate buffer (pH 6.0) for 20 minutes. Goat anti-mouse Fab fragment (Jackson ImmunoResearch Laboratories) 1:65 was used for 30 minutes at 37jC for blocking before anti-V5 immunostaining. Sections were then incubated in protein blocker ( for V5, CD31, and GFP) or 5% normal donkey serum in universal buffer ( for CTGF). Primary antibodies were diluted and used under the following conditions: V5 (1:200), CD31 (1:50), GFP (1:200) in primary antibody diluent, and CTGF (1:100) in 5% normal donkey serum overnight at 4jC. Secondary antibodies were diluted and used under following conditions: biotin-conjugated universal secondary antibody for 4 minutes at 50jC; biotin-conjugated goat anti-rat IgG 1:100; biotinconjugated goat anti-rabbit IgG 1:500; and biotin-conjugated donkey antigoat antibody 1:200 for 45 minutes at 37jC. Tissues were treated with Auto Blocker to inhibit endogenous peroxidase activity. For detection, sections were incubated in RTU VectaStain Elite ABC reagent (Vector Laboratories
Microvessel density analysis. Analysis was done according to standard procedures we have published previously with DRS tumors (2, 3, 34) . Tissue sections were stained for CD31 as described above. Sections were scanned at Â100, and five random areas per tumor section were selected. Vessels in these fields were counted (at Â400) by an observer blinded to experimental conditions. The average vessel count was determined for each specimen.
Statistical analysis. Tumors from each condition were analyzed, and average tumor weight and average microvessel counts were compared with these values from their matching control tumors for statistical relevance using the unpaired t test. Statistical analyses used GraphPad Prism for Macintosh version 3.0 (GraphPad Software, San Diego, CA). P < 0.05 was considered statistically significant.
Results
Differential expression of connective tissue growth factor in tumor-promoting human prostate stromal cell lines. Our previous studies using the DRS xenograft model showed that several human prostate stromal cell lines differentially promote LNCaP prostate cancer cell tumorigenesis (2) . Stromal cellpromoted tumors exhibited a significantly elevated rate of angiogenesis and this was TGF-h1 regulated (2, 3) . Notably, the HTS-40C and the HTS-2T human prostate stromal cell lines exhibited opposing effects. In two-way DRS xenografts constructed of cancer cells and stromal cells in the absence of extracellular matrix (Matrigel), the HTS-40C/LNCaP combinations resulted in a 65% tumor incidence, whereas HTS-2T/LNCaP combinations were nontumorigenic (0% tumor incidence; ref.
2).
To address potential mechanisms, gene expression profiles in HTS-40C and HTS-2T stromal cells were compared using cDNA microarray analyses. This analysis showed that 12 previously characterized genes were elevated by 3-to 31-fold in the protumorigenic HTS-40C stromal cell line compared with HTS-2T. These genes are listed in Table 1 . Expression of several of these genes is associated with reactive stroma that forms at sites of wound repair, microbial invasion, or carcinoma as we have reported previously (1, 32, 35) . Of these, CTGF is a known inducer of angiogenesis (36) , is TGF-h1 regulated in stromal cells (18, (37) (38) (39) , and has been reported to directly enhance TGF-h1 receptor-ligand binding (40) . Our microarray data suggested that CTGF message was 4.5-fold higher in HTS-40C cells compared with HTS-2T cells. Further analysis confirmed this with RT-PCR and showed that CTGF message expression was severalfold higher in HTS-40C cells relative to HTS-2T cells as shown in Fig. 1A .
Although the HTS-2T stromal cell line did not support LNCaP tumorigenesis in matrix-free conditions (two-way tumors), HTS-2T cells did promote LNCaP tumors (incidence, rate of tumorigenesis, and angiogenesis) when combined with Matrigel matrix in three-way DRS xenografts that are constructed with cancer cells, stromal cells, and Matrigel matrix (2, 3). Matrigel matrix is high in TGF-h1 and we have reported that inhibiting TGF-h1 activity in Matrigel lowers the rate of tumorigenesis and angiogenesis in three-way DRS tumors (3). Accordingly, we next determined whether TGF-h1 could induce CTGF expression in human prostate HTS-2T stromal cells. As shown in Fig. 1B , HTS-2T cells in control conditions exhibited low expression, whereas HTS-2T cultures exposed to TGF-h1 (100 pmol/L, 24 hours) exhibited elevated CTGF message expression. This is in agreement with previous reports showing TGF-h1 regulation of CTGF expression in other stromal cell lines (15, 19) . Expression of connective tissue growth factor in prostate stromal cells promotes angiogenesis and LNCaP tumorigenesis. A construct containing the full-length human CTGF cDNA (kindly provided by Dr. Gary Grotendorst) was used to construct a bicistronic retroviral vector (pBMN-CTGF-I-EGFP) containing CTGF followed by an IRES and EGFP for detection of expression. Either vector control (pBMN-I-EGFP) or the CTGF-containing retrovirus preparations were used to infect the mouse prostate stromal cell line (C57B) and cells were analyzed for fluorescence 48 hours later as described in Materials and Methods. Figure 2A shows infected and EGFP-expressing C57B stromal cells before use in the DRS xenograft. C57B cells routinely exhibited a 90% infectivity rate or higher (data not shown). Western blot analysis showed overexpression of the mature form of CTGF (f38 kDa) in the experimental cell conditioned medium and low endogenous levels in the control infected cultures (Fig. 2B) . Shorter fragments were also observed (Fig. 2B, band A and band B) , which have been reported in the conditioned media of CTFGsecreting cells by others (41) .
To evaluate the effects of CTGF expression from prostate stromal cells in three-way LNCaP tumors in nude mice, we inoculated cell combinations in either complete Matrigel or a modified matrix composed of a 1:1 mix of GFR Matrigel together with neutralized Vitrogen 100 collagen type I (GFR Matrigel/ Vitrogen) to reduce bioactive factors in the matrix component. S.c. three-way DRS xenograft tumors were constructed in male nude mice using 2 Â 10 6 LNCaP cells, and 1 Â 10 6 control C57B (EGFP-expressing vector only) or CTGF-expressing C57B prostate stromal cells and the different Matrigel matrix preparations as described in Materials and Methods. Tumors were harvested at day 13 postinoculation because our previous studies have shown that day 10 to day 14 postinoculation is the optimal time frame to assess initial rate of angiogenesis and tumorigenesis (2, 3, 34) . It should be noted that control or CTGF-transduced C57B cells inoculated alone or with matrix were nontumorigenic (data not shown) similar to our previous report (2) . As shown in Fig. 2C , tumors were fluorescent in situ before removal. This confirmed transgene expression and viability of the engineered C57B stromal cells in the tumor xenograft.
Tumors exhibited a typical arrangement of LNCaP carcinoma cell clusters, surrounded by stromal cells, matrix, and vessels as shown in Fig. 3A and B , similar to what we have reported previously (2) . There were no particular differences in histology or ratio of carcinoma to stromal cells in experimental tumors compared with control tumors. Prostate stromal cells engineered with the CTGF transgene in tumors were positive for both EGFP (Fig. 3C) and CTGF (Fig. 3D) proteins, and were immediately adjacent to clusters of LNCaP carcinoma cells. Immunostaining for CD31 as an endothelial marker showed an obvious difference in vessels. The density of CD31-positive microvessels in CTGFexpressing xenografts (Fig. 3F ) seemed higher compared with control xenografts (Fig. 3E) . Microvessel counts confirmed this. In complete Matrigel conditions, LNCaP xenograft tumors constructed with CTGF-expressing prostate stromal cells exhibited a microvessel density of 10.60 F 1.35 compared with 6.16 F 1.60 in vector-only control tumors (n = 25 fields, five tumors each, mean F SE, P < 0.05; Fig. 4A ). This represented a 72% increase in vessel density in the stromal CTGF-expressing tumors. The increase in vessel density correlated with elevated tumor mass. The mean wet weight of stromal CTGF-expressing LNCaP tumors was 24.42 F 0.76 mg compared with 18.08 F 1.54 mg (n = 5, mean F SE, P < 0.01; Fig. 4B ) in control tumors, indicating that stromal CTGF expression produced a 35% increase in tumor mass when xenografts are constructed in complete Matrigel conditions. Significant differences in angiogenesis were even more pronounced in the low growth factor-modified matrix (GFR Matrigel/Vitrogen 100) conditions. CTGF-expressing tumors exhibited an average microvessel density of 10.10 F 1.73 compared with 4.70 F 1.00 in control tumors, representing a 115% increase over control (n = 30, from six tumors in each condition, mean F SE, P < 0.01; Fig. 4C ). The stromal CTGFexpressing LNCaP tumors constructed in the GFR-modified matrix showed an average wet weight of 17.58 F 0.60 mg compared with 12.97 F 0.71 mg in control tumors (n = 18 in the CTGF experimental and n = 17 in the control, mean F SE, P < 0.0001; Fig. 4D ), representing a 36% increase in tumor mass.
Regulated expression of CTGF-V5-His in 3T3 fibroblasts promotes LNCaP tumorigenesis. To confirm and extend the findings with retroviral transduced C57B cells, the GeneSwitch System (Invitrogen) was used to engineer 3T3 stromal cell lines with mifepristone-regulated expression of an epitope-tagged CTGF-V5-His ( fusion protein). Cultures at 80% to 100% confluence were induced with 100 pmol/L mifepristone for 24 to 48 hours. Western blot analysis for the V5 epitope showed an inducible 41 kDa CTGF-V5-His band in the conditioned media (Fig. 5A) . DRS xenograft tumors were generated in nude mice using 2 Â 10 6 LNCaP cells combined with g-irradiated 5 Â 10 5
GeneSwitch-3T3 pGene CTGF-V5-His cells and complete Matrigel (three-way DRS xenograft conditions). Irradiated engineered 3T3 cells (800 rad) were used because these cells remain viable, exhibit regulated transgene expression, and have a low proliferative rate relative to wild-type NIH 3T3 cells. Mice were given mifepristone or vehicle i.p. every 48 hours as described in Materials and Methods. Our previous studies have shown that this protocol of mifepristone treatment has no ill effect on nude mice and does not affect control tumor biology (2, 34) . Resulting tumors were harvested 10 days postinoculation. Immunohistochemistry showed tightly regulated CTFG-V5-His protein expression in vivo (Fig. 5B) . No expression was noted in tumors derived from vehicle control-treated animals (Fig. 5C ). Tumors exhibited a typical carcinoma phenotype similar to the LNCaP/ C57B combinations, although the tumors were considerably more heterogeneous with more focal nodules of carcinoma and other areas that seemed to have little carcinoma growth. There was, however, no apparent difference in histopathology noted between vehicle control and mifepristone-treated animals. LNCaP DRS tumors from mifepristone-treated animals exhibited a 25% average increase in wet weight as shown in Fig. 5D . The mean weight of control tumors was 17.91 F 1.04 mg, whereas tumors from mifepristone-treated animals averaged 22.41 F 1.76 mg (P < 0.05, n = 12 tumors each). The tumors exhibited a very heterogeneous density of microvessels, as might be expected, due to the nodular and heterogeneous histopathology. This was obvious at low-power observation (data not shown). The heterogeneous nature of the vessel density patterns in these tumors was not compatible with the microvessel-counting protocol (see Materials and Methods) as the accuracy of this method is dependent on uniform vessel distribution. Accordingly, no attempt was made to quantitate microvessel density in these tumors as these data would not be accurate.
Discussion
To date, no effective approach exists to manipulate overexpression of a transgene in the stromal compartment in a tissuespecific manner in situ. Accordingly, we have used the DRS xenograft tumor approach to test the biological consequences of differential transgene expression in the reactive stroma compartment of an experimental human tumor in a nude mouse host. Our previous studies have shown that use of different human prostate stromal cell lines result in vast differences in LNCaP tumorigenesis in vivo (2). Furthermore, we have shown that the endogenous TGFh1 activity in complete Matrigel is responsible for this difference in both angiogenesis and tumorigenesis (3). Our current study shows that CTGF may mediate TGF-h1 actions in the prostate stromal cells. Expression of a CTGF transgene in the reactive stromal compartment of LNCaP DRS xenograft tumors resulted in enhanced tumorigenesis that was correlated with a more rapid rate of angiogenesis. We conclude from these data that CTGF may be an important regulator of tumor-reactive stroma and angiogenesis.
Our studies and others have suggested that reactive stroma in carcinomas is an important process associated with early events in tumorigenesis, including the formation of a wound repair type of matrix and enhanced angiogenesis (1-3, 32 ). Reactive stroma is remarkably similar in most carcinomas. Typically, carcinomaassociated reactive stroma is composed of activated fibroblasts and myofibroblasts, characteristic of a wound repair-type stroma (1, 32, 35) . A key feature of wound repair stroma is rapid and elevated angiogenesis. In wounding, platelet-released TGF-h1 and platelet-derived growth factor function to regulate stromal cell phenotype changes and to stimulate stromal cell migration, matrix production, and angiogenesis. TGF-h1 is overexpressed by cancer epithelial cells in most carcinomas, including prostate cancer (32, 35) . Moreover, CTGF is TGF-h1 regulated in a diverse set of cell types, including human prostate stromal cells as reported here (15) (16) (17) (18) (19) . In addition, CTGF has been shown to stimulate a wound repair type of stroma in several key studies and has been shown to mediate, in part, TGF-h1-induced matrix remodeling (20) . Hence, it is important to determine whether CTGF mediates a TGF-h1-stimulated reactive stroma response in cancer and whether this reactive stroma is tumor promoting. Data reported here address this question directly and suggests that TGF-h1 stimulated CTGF expression in carcinoma-associated reactive stroma, promotes angiogenesis, and results in enhanced tumorigenesis.
It is becoming clearer that the classic regulators of wound repair play an important role in carcinoma-reactive stroma and CTGF biology. For example, both fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor have been reported to stimulate CTGF expression (25, 42) . FGF-2 expression is also TGF-h1 regulated in fibroblasts from the prostate gland and other tissues (43, 44) . Hypoxia will induce CTGF expression via a hypoxiainducible factor-1a pathway (45) . In addition, thrombin and plasma clotting actor VIIa also induce CTGF expression (46) . Accordingly, several factors and conditions associated with wound repair are known to affect CTGF expression and many of these factors and conditions are likely to play a role in tumor-associated reactive stroma.
The specific mechanisms of how CTGF or closely related family members directly affect reactive stromal cells in the tumor microenvironment is not fully understood. It is known that both CTGF and Cyr61 promote fibroblast adhesion through integrin a6h1 and that this process requires cell surface heparan sulfate proteoglycans (47) . Cry61 and CTGF also stimulated migration and proliferation of fibroblasts, as well as endothelial cells (24, 48) . In addition, CTGF also affects matrix production and remodeling. For example, CTGF was shown to stimulate fibronectin expression via a p42/44 mitogen-activated protein kinase and phosphoinositide 3 kinase/protein kinase B pathway (49) . It will be important to dissect key CTGF signaling pathways in reactive stroma associated with tumors. Key components of these mechanisms may be useful as targets of therapeutic approaches directed at the tumor microenvironment.
The DRS model described in this study brings the opportunity to use highly efficient gene delivery and stable gene integration A, microvessel density, as assessed by CD31-positive structures, counted by a blinded observer (n = 25 fields, five tumors for each group). *Statistically significant increase in tumor microvessel density for DRS tumors generated in the presence of stromal cells expressing CTGF (P < 0.05). B, tumor wet weight (n = 5). *Statistically significant increase in wet weights of CTGF-expressing tumors when compared with control tumors (P < 0.01). C and D, microvessel densities and tumor weight were compared between the LNCaP tumors generated in the presence of C57B cells engineered to express CTGF (CTGF ) or vector control C57B stromal cells (Control ), in the low growth factor modified matrix (GFR Matrigel/Vitrogen 100) conditions at day 13 postinoculation. C, microvessel density, as assessed by CD31-positive structures, counted by a blinded observer (n = 30 fields, six tumors for each group). *Statistically significant increase in tumor microvessel density for DRS tumors generated in the presence of stromal cells expressing CTGF (P < 0.01). D, tumor wet weight (n = 17 in the control and n = 18 in the CTGF experimental). *Statistically significant increase in wet weights of CTGF expression tumors when compared with control tumors (P < 0.0001).
of retroviral-infected mouse prostate stromal cell lines to study the roles of epithelial cell-stromal cell interactions in carcinoma tumorigenesis and progression. Accordingly, the DRS model has allowed for the ability to dissect out the roles of individual growth factors in the reactive stroma compartment of a tumor. Data reported here represent the first study to show that expression of CTGF in the tumor microenvironment stromal cells of an experimental epithelial cancer functions to stimulate angiogenesis and tumor growth.
Emerging data supports the concept that the reactive stromal tumor microenvironment functions to affect the rate of tumorigenesis in most epithelial carcinomas studied to date. Accordingly, it is likely that the biological components and specific mechanisms of reactive stroma can be used both as prognostic indicators and as targets of therapeutics. This study shows that CTFG is a TGF-h1-regulated and stromal-expressed factor that promotes tumorigenesis and is, therefore, a theoretical target for therapeutics focusing on tumor-associated reactive stroma biology. 
